Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5 | P01031 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567019 | 0.91 | HIF1A (0.48) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6565978 | 0.89 | CASR (0.52) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6566599 | 0.85 | FPR2 (0.53) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6564522 | 0.81 | KMT2A (0.51) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6568031 | 0.80 | KMT2A (0.52) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6567575 | 0.79 | KMT2A (0.54) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6564452 | 0.79 | KMT2A (0.56) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6564613 | 0.76 | HIF1A (0.50) | C5KMT2AMEN1MAPTHTT | |
| SCHEMBL6567917 | 0.75 | IMPDH2 (0.51) | C5KMT2AMEN1MAPTGAA | |
| SCHEMBL6711898 | 0.75 | KMT2A (0.49) | C5KMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | C5 2265/4885KMT2A 3137/4885MEN1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.